Clinical Genome Sequencing (CLIA / CAP)

Our clinical genome sequencing services are run within our CLIA-certified, CAP-accredited laboratory, harnessing the advanced capabilities of next-generation short-read and long-read sequencing technology. These tests enable clinicians to obtain a complete picture of the genome, including complex variants and difficult-to-sequence regions.

These effective assays can help you tackle complex biological questions with complete genome data, fueling your innovations in precision medicine, biomarker discovery, and personalized therapies.

If you require more targeted genomic analyses for your clinical applications, explore our clinical whole exome sequencing services. We also offer research use only (RUO) whole genome sequencing for your non-clinical needs.

Analyze thousands of genetic markers at once

Microarray Solutions

Features & Benefits

Flexible data analysis and regulatory oversight to meet study requirements

PCR-free protocols provide unbiased sequence information

Ph.D.-level support during the entire project, including free consultations

Variant confirmation via Sanger sequencing available for a streamlined CLIA-compliant workflow

FROM SEQUENCING TO DISCOVERY

1. SUBMIT SAMPLES

Submit DNA or blood sample

2. SEQUENCE

Sequencing on the Illumina short-read or PacBio long-read platforms

3. ANALYZE DATA

Receive raw data files and variant report

Service Levels

Service Level*	Data & Report (FASTQ, BAM & VCF)	QA Oversight	Lab Director Signature
Regulated Environment
CLIA-Validated Service

Included | Not Available

*All service levels are performed by CLIA-trained personnel in a CLIA-certified lab with CLIA-qualified equipment.

Technical Resources

Case Study | Developing an Inclusion and Safety Monitoring Assay for a Cell Therapy Clinical Trial

A biopharma company required a partner for clinical trial support with an immediate need for biomarker assay development and validation using NGS. Read the case study to learn how this company was able to streamline clinical testing and accelerate the timeline of its phase 1/2 study.